Hydrazine derivatives

ABSTRACT

HYDRAZINE DERIVATIVES OF THE FORMULA   Y&lt;(-(X1-1,2-PHENYLENE)-CO-N(-NH2)-(X2-1,2-PHENYLENE)-)   ARE PHARMACEUTICALLY ACCEPTABLE, ACID-ADDITION SALTS THEREOF, AND WHEREIN X1 IS H OR CL, X2 IS H, CL, CH3O OR CF3 AND Y IS -O-, -S-, -SO2-, -NH-, -N(CH3), -CO-, -CH2-, -CH(CH3)- OR -C(CH3)2- ARE USEFUL AS ANTIEPILIPTIC AGENTS.

United States Patent 3,663,533 HYDRAZINE DERIVATIVES Michio Nakanishi, 756 Shinborimachi, Nakatsu, Oita,

Japan; Hiroshi Yuki, 1336 ()aza-Hirotsu, Yoshitomimaehi, Chikujogun, Fukuoka, Japan; and Tomio Muro, 2275 Kanaya-Uenocho, Nakatsu, Oita, Japan No Drawing. Filed May 6, 1970, Ser. No. 35,233 Claims priority, applic/atiorgaapan, May 6, 1969,

Int. Cl. C07d 93/42, 87/54, 53/00 [7.5. Cl. 260-239.3 Claims ABSTRACT OF THE DISCLOSURE Hvdrazine derivatives of the formula co. c --CH(CH or s)a-' are useful as antiepileptic agents.

This invention relates to novel and therapeutically valuable hydrazine derivatives.

The hydrazine derivatives of the present invention have the formula.

Compounds in accordance with Formula I may be produced by the reaction of an alkali metal salt of a compound of the formula sodium amide, lithium amide) or alkali metal hydride (e.g. sodium hydride).

(b) By the reaction of a compound of the formula /cooa H2 wherein R is alkyl of 1 to 4 carbon atoms, and X X and Y are as above defined, with an alkali metal amide (e.g. sodium amide).

The hydrazine derivatives of Formula I, as well as their pharmaceutically acceptable, acid-addition salts, have excellent antiepileptic action and are useful in the treatment of epileptic fits. For example, the compounds of Formula I listed below (A, B, C, D and E) have pharmacological properties as herein after set forth.

(A) 10-amino-7-chloro-10,1l-dihydro-SH-dibenzo [b,e]'

[1,4] diazepin-l l-one (B) 10-amino-l0,ll-dihydrodibenzo [b,f] [1,4]

thiazepin- 1 l-one (C) 10-amino-5-methyl-10,1l-dihydro-SH-dibenzo [b,e]

[1,4] diazepin-l l-one (D) 5-amino-5,6-dihydromorphantridine-6,1 l-dione (E) S-amino-l 1,1 l-dimethyl-5,6-dihydromorphanthridin- 6-one ANTISPASMODIC ACTION The test compounds were administered intraperitoneally to dd-strain mice (male, 20-25 g.), each group consisting of six mice. After an hour, the silver electrode of the electroshock seizure apparatus (designed by Lowell A. Woodbury and Virginia D. Davenport: see, Archives Internationales de Pharmacodynamie et de Therapie, 1952, volume 42, pages 97-102.) was brought into contact with the cornea and an alternating current (2000 volts, 12.5 milliamperes) was appied for 0.2 second to induce spasm. The seizure rate was measured to prepare the dose response curve and determine the ED value (the dose required to lower the seizure rate by 50% against the control mice). The results are shown in Table I.

TABLE I TOXICITY The LD values of 10-amino-5-methy1-10,11-dihydro SH-dibenzo [b,e] [1,4] diazepin-ll-one in mice are as follows:

Intraperitoneal Z320 Subcutaneous 320 Oral 320-640 LD (mg/kg. body Weight) The compounds in accordance with Formula I and pharmaceutically acceptable, acid-addition salts thereof may be administered safetly per se or in the form of a pharmaceutical composition in admixture with a suitable carrier or adjuvant, administrable orally, without causing harm to the host.

The pharmaceutical composition can take the form of tablets, granules, powders, etc. The following are examples of compositions of the invention which may be administered for pharmaceutical purposes.

1) 250 mg. tablets are prepared from the following composition:

Compound C 250 Lactose 50 Starch l8 Microcrystalline cellulose Magnesium stearate 2 Total 330 (2) 50 wt. percent powders are prepared from the following composition:

Wt. percent Compound C 50 Lactose 35 Starch Total 100 A mixture of 4.8 g. of 7-chloro-10,1l-dihydro-SH-dibenzo[b,e] [1,4]diazepin-11-one, 40 ml. of anhydrous dioxane and 0.86 g. of sodium amide is refluxed for 2 hours. After cooling and addition of 5 ml. of anhydrous dimethylformamide, there is added to the resulting mixture 4.4 g. of O-(2,4-dinitrophenyl)hydroxylamine at C. The mixture is stirred for 2 hours at 20 C. and then poured into 100 ml. of water. The crystals formed are collected by filtration, washed with water, air-dried and recrystallized from ethyl acetate to give 4.9 g. of 10-amino-7- chloro10,1l-dihydro-SH-dibenzo[b,e,] [1,4]diazepin 11- one as pale yellow crystals melting at 206-207 C.

EXAMPLE 2 A mixture of 4.2 g. of 10,11-dihydrodibenz[b,f][1,4] oxazepin-ll-one, 40 ml. of anhydrous dioxane and 0.9 g. of sodium amide is refluxed for 3 hours. After cooling and addition of 5 ml. of anhydrous dimethylformamide, there is added to the resulting mixture 4.4 g. of O-(2,4- dinitrophenyl)hydroxylamine. The mixture is stirred for 2 hours at room temperature, and then poured into 100 ml. of water. The crystals formed are collected by filtration. washed with water, air-dried and recrystallized from methanol to give 4 g. of 10-amino-10,ll-dihydrodibenz [b,f][1,4]oxazepin-11-one as white crystals melting at 151153 C.

EXAMPLE 3 A mixture of 6.5 g. of methyl o-(2-amino-4-trifluoromethylphenylthio)-benzoate, 40 ml. of anhydrous dioxane and 0.9 g. of sodium amide is refluxed for 4 hours. After cooling to room temperature and addition of 5 ml. of anhydrous dimethylformamide, there is added to the resulting mixture 4.4 g. of O-(2,4-dinitrophenyl)hydroxylamine at 20 C. The resulting mixture is stirred for 2 hours at room temperature, and then poured into 100 ml. of water. The crystals formed are collected by filtration, washed 4 with water, air-dried and recrystallized from ethanol to give 5.4 g. of 10-amino-8-trifluoromethyl-10,1l-dihydrodibenzo[b,f] [1,4]thiazepin-11-one as white needles melting at 142-145 C.

EXAMPLE 4 A mixture of 4.4 g. of 5,6-dihydromorphanthridine- 6,1l-dione, 40 ml. of anhydrous dioxane and 0.9 g. of sodium amide is refluxed for 3 hours. After cooling and addition of 5 ml. of anhydrous dimethylformamide, there is added to the resulting mixture 4.4 g. of O-(2,4-dinitrophenyl)hydroxylamine at 20 C. The mixture is stirred for 2 hours at 20 C., and then poured into ml. of water. The crystals formed are collected by filtration, washed with water, air-dried and recrystallized from ethanol to give 4.2 g. of 5-amino-5,6-dihydromorphanthridine-6,11-dione melting at 153-156" C.

EXAMPLE 5 A mixture of 4.4 g. of 11-methyl-5,6-dihydromorphanthridin-6-one, 40 ml. of anhydrous dioxane and 0.9 g. of sodium amide is refluxed for 3 hours. After cooling and addition of 5 ml. of anhydrous dimethylformamide, there is added to the resulting mixture 4.4 g. of O-(2,4- dinitrophenyl)hydroxylamine at 20 C. The mixture is stirred for 2 hours at 20 C., and then poured into 100 ml. of water. The crystals formed are collected by filtration, washed with water, air-dried and recrystallized from methanol to give 4.1 g. of S-amino-l1-methyl-5,6-dihydromorphanthridin-6-one melting at 142145 C.

EXAMPLE 6 A mixture of 4.6 g. of 11,11-dimethyl-5,6-dihydromorphanthridin-6-one, 50 ml. of anhydrous dioxane and 0.9 g. of sodium amide is stirred for 4 hours at room temperature. To the reaction mixture is added 4.4 g. of O-(2,4- dinitrophenyl)hydroxylamine and stirred for 1 hour at 20 C. Then the reacting products are poured into ml. of water. The crystals formed are collected by filtration, washed with water, air-dried and recrystallized from ethanol to give 4.3 g. of 5-amino-1l,1l-dimethyl-5,6-dihydromorphanthridin-6-one melting at 223-225 C.

EXAMPLES 7-13 Following the procedures of above examples, but substituting equivalent amounts of appropriate starting materials, the following hydrazine derivatives are also produced:

(7) IO-amino 10,11 dihydrodibenzo[b,f] [1,4]thiazepin-ll-one, white needles melting at 173-174.5 C.;

(8) l0-amino-8-methyl-1O,11-dihydr0dibenzo[b,f] [1,4] thiazepin-ll-one, white needles melting at 178-182 C.;

(9) 10-amino-5-methyl-lO,1 1-dihydro5H-dibenzo[b,e] [1,4]diazepin-1l-one, yellow crystals melting at 176- 179 C.;

(10) 10-amino-7-methoxy-10,11 dihydrodibenzo[b,f] [1,4]thiaZepin-11-one, white needles melting at 15.3- 156 C.;

(11) 10-amino-2-chloro 10,11 dihydrodibenzo[b,f] [1,4]oxaZepin-11-one melting at 130132 C.;

(12) 10-amino-10,11 dihydrodibenzo[b,f] [1,4]thiazepin-11-one-5,5-dioxide melting at 234236 C.; and

(13) S-amino-S,6-dihydromorphanthridin-6-one melting at -173 C.

What is claimed is:

1. A hydrazine of the formula and pharmaceutically acceptable, acid-addition salts thereof, wherein X is H or Cl, X is H, Cl, CH CH O or CE;

2. A compound according to claim 1 having the name 10-amino-7-ch1oro-10,1l-dihydro 5H dibenzo[b,e] [1,4] diazepin-l l-one.

3. A compound according to claim 1 having the name -amino-10,11 dihydrodibenzo[b,f] [l,4]oxazepin 11- one.

4. A compound according to claim 1 having the name 10-amino-8-trifluoromethyl 10,11 dihydrodibenzo[b,f] [1,4] thiazepin-l l-one.

5. A compound according to claim 1' having the name 10-amino-10,11 dihydrodibenzo [b,f] [1,4]thiazepin 11- one.

6. A compound according to claim 1 having the name 10-amino-8-methyl 10,11 dihydrodibenzo[b,f] [1,4]thiazepin- 1 l-one.

7. A compound according to claim 1 having the name 10-amino-5-methyl-10,1l-dihydro-SH dibenzo[b,e][l,4] diazepin- 1 l-one.

8. A compound according to claim 1 having the name 10-amino-7-methoxy-10,11 dihydrodibenzo[b,f] [1,4]thiazepin-l l-one.

9. A compound according to claim 1 having the name 5-amino-5,6-dihydromorphanthridinc-6,1 l-dione.

10. A compound according to claim 1 having the name S-amino-l 1-methyl-5,6-dihydromorphanthridin-6-one.

11. A compound according to claim 1 having the name 5-amino-11,11-dimethyl-5,6 dihydromorphanthridin 6- one.

12. A compound according to claim 1 having the name 10-amino-2-chloro-10,11 dihydrodibenzo[b,f] [1,4]oxazepin-1 l-one.

13. A compound according to claim 1 having the name 10-amino-10,11 dihydrodibenzo [b,f] [1,4]thiazepin 11- one-5,5-dixoide.

14. A compound according to claim 1 having the name S-amino-S,6-dihydromorphanthridin-6-one.

15. A method for producing a hydrazine derivative in accordance with claim 1 which comprises reacting a compound of the formula 0 Me II I .C N x1 I I 3 wherein Me is alkali metal and X X and Y are as defined in claim 1, with O-(2,4-dinitrophenyl)hydroxylamine.

References Cited UNITED STATES PATENTS 3,531,472 9/1970 Nakanishi et al. 260-239.3 T

HENRY R. JILES, Primary Examiner R. T. BOND, Assistant Examiner US. Cl. X.R. 424--244, 275 

